Intensity therapeutics, inc. announces that int230-6 achieved 100% complete response rate in preclinical models of malignant peripheral nerve sheath tumors (mpnst)

Shelton, conn. , june 30, 2025 /prnewswire/ -- intensity therapeutics, inc. (nasdaq: ints) ("intensity" or "the company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that int230-6 achieved complete responses in a murine models of malignant peripheral nerve sheath tumor ("mpnst").
INT Ratings Summary
INT Quant Ranking